首页> 外文OA文献 >Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2

【2h】

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2

机译：添加性黑色素瘤抑制与体内磷脂 - 缀合的TLR7激动剂和全身IL-2

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tomoko Hayashi; Michael Chan; John T. Norton; Christina C.N. Wu; Shiyin Yao; Howard B. Cottam; Rommel I. Tawatao; Maripat Corr; Dennis A. Carson; Gregory A. Daniels;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2 [J] . Tomoko Hayashi, Michael Chan, John T. Norton, Melanoma research . 2011,第1期

机译：病灶内磷脂结合的TLR7激动剂和全身性IL-2抑制加性黑素瘤
2. 451?Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8 T cell expansion to enhance anti-tumor immunity [J] . Annah Rolig, Daniel Rose, Saul Kivimae, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：451？组合Bempegaldesleukin（CD122-优先IL-2途径激动剂）和NKTR-262（TLR7 / 8激动剂）对全系统CD8 T细胞扩张的本地先天激活，增强抗肿瘤免疫力
3. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma [J] . Ogawa Hiromi, Luxardi Guillaume, Kirane Amanda, The Journal of investigative dermatology. . 2018,第6期

机译：T细胞与伊醌IL-2诱导的局部免疫应答与咪喹莫特和视黄醇组合在过境转移性黑色素组合中
4. Polymeric controlled delivery of il-2 and doxorubicin against a murine melanoma model [C] . I. Shipanova-Kadjyala, S. Liu, H-Q. Mao K. W. Leong International symposium on controlled release of bioactive materials;Consumer and diversified products conference . 1998

机译：il-2和阿霉素对小鼠黑色素瘤模型的聚合控制递送
5. Manganese Doped Silica Nanoparticles for Acidic pH Responsive TLR7 Agonist Delivery [D] . Dong, Fangyi. 2021

机译：锰掺杂二氧化硅纳米粒子用于酸性pH响应TLR7激动剂递送
6. Additive melanoma suppression with intralesional phospholipid conjugated TLR7 agonists and systemic IL-2 [O] . Tomoko Hayashi, Michael Chan, John T. Norton, -1

机译：添加性黑色素瘤抑制与体内磷脂缀合的TLR7激动剂和全身IL-2
7. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines [O] . Forum Patel, Reason Wilken, Barbara Burrall, 2014

机译：基于当前的NCCN指南，用于治疗II型和IV M1A转移性黑素瘤的内部IL-2的详细方案

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2

著录项

引文网络

相似文献

相关主题

期刊订阅